ArticlePLoS neglected tropical diseases2019
Clinical and epidemiological features of paracoccidioidomycosis due to Paracoccidioides lutzii.
Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Genetic background and immune response in paracoccidioidomycosis: A systematic review and meta-analysis of single nucleotide variants.PLoS neglected tropical diseases · 2026Pooled it
- Proteomic Changes inJournal of proteome research · 2025Article
- Article
- Single ulcers on the tongue dorsum: differential diagnosis between paracoccidioidomycosis and squamous cell carcinoma.Medicina oral, patologia oral y cirugia bucal · 2024Article
- Article
- Phenotypic characterization of cryptic species in the fungal pathogenbioRxiv : the preprint server for biology · 2024Article
- Paracoccidioidomycosis cases by Paracoccidioides lutzii in southeastern Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Mycological diagnosis of paracoccidioidomycosis in a hospital from a nonendemic area: classical and molecular methodsBiomedica : revista del Instituto Nacional de Salud · 2023Article
- Make the diagnosis - Second partBiomedica : revista del Instituto Nacional de Salud · 2023Article
- Paracoccidioides and Paracoccidioidomycosis in the 21st Century.Mycopathologia · 2023Review
- Development of a Multiplex qPCR Assay for Fast Detection and Differentiation of Paracoccidioidomycosis Agents.Journal of fungi (Basel, Switzerland) · 2023Article
- Paracoccidioidomycosis: Current Status and Future Trends.Clinical microbiology reviews · 2022Review
- Paracoccidioidomycosis: What We Know and What Is New in Epidemiology, Diagnosis, and Treatment.Journal of fungi (Basel, Switzerland) · 2022Review
- PbGP43 Genotyping Using Paraffin-Embedded Biopsies of Human Paracoccidioidomycosis Reveals a Genetically Distinct Lineage in the Paracoccidioides brasiliensis Complex.Mycopathologia · 2022Article
- Clinical and Eco-Epidemiological Aspects of a Novel Hyperendemic Area of Paracoccidioidomycosis in the Tocantins-Araguaia Basin (Northern Brazil), Caused byJournal of fungi (Basel, Switzerland) · 2022Article
- Article
- Exploring genetic diversity, population structure, and phylogeography inStudies in mycology · 2021Article
- Diagnosis of Pulmonary Infections Due to Endemic Fungi.Diagnostics (Basel, Switzerland) · 2021Review
- An update on the occurrence of Paracoccidioides species in the Midwest region, Brazil: Molecular epidemiology, clinical aspects and serological profile of patients from Mato Grosso do Sul State.PLoS neglected tropical diseases · 2021Article
- A New Duplex PCR-Assay for the Detection and Identification ofJournal of fungi (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe fungus Paracoccidioides lutzii was recently included as a new causative species of paracoccidioidomycosis (PCM) and most cases have been reported from Brazil. According to available epidemiological information, P. lutzii is concentrated in the Middle-West region in Brazil, mainly in the state of Mato Grosso. However, clinical and laboratorial data available on patients infected with P. lutzii remain extremely limited. METHODOLOGY/MAIN
findingsThis work describes the clinical manifestations of 34 patients suffering from PCM caused by P. lutzii, treated along 5 years (2011-2017) at a reference service center for systemic mycoses in Mato Grosso, Brazil. Adult rural workers (men), aged between 28 and 67 predominated. All patients had the chronic form of the disease, and the oral mucosa (n = 19; 55.9%), lymph nodes (n = 23; 67.7%), skin (n = 16; 47.1%) and lung (n = 28; 82.4%) were the most affected sites. Alcohol intake (n = 19; 55.9%) and smoking (n = 29; 85.3%) were frequent habits among the patients. No patient suffered from any other life-threatening disease, such as tuberculosis, cancer or other inflammatory or infectious parasitic diseases. The positivity in culture examination (97.1%) was higher than that found for the direct mycological examination (88.2%). Particularly, one patient presented fungemia at diagnosis, which lead to his death. The time elapsed between the initial symptoms and the initiation of treatment of PCM caused by P. lutzii was 19.7 (31.5) months, with most patients diagnosed 7 months after the symptoms' onset. CONCLUSIONS/SIGNIFICANCE: Compared with the classical clinical-epidemiological profile of PCM caused by P. brasiliensis, the results of this descriptive study did not show significant clinical or epidemiological differences that could be attributed to the species P. lutzii. Future studies may confirm or refute the existence of clinical differences between the two fungal species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.